Figure 1. Hepatic and Pancreatic Uptake of Intravenously Administered ⁵⁹Fe-NTBI is Impaired in Slc39a14^−/− Mice.

(A) In vivo ⁵⁹Fe-NTBI uptake by various tissues of 6-wk-old wild-type (WT, n = 5) and Slc39a14^−/− mice (n = 10). Tissue uptake of ⁵⁹Fe from NTBI was calculated as a percentage of whole-body cpm. (B) Immunoblot analysis of SLC39A14 in liver homogenates from WT, Slc39a14^+/−, and Slc39a14^−/− mice (n = 4 per group). (C) In vivo ⁵⁹Fe-NTBI uptake by the liver in WT (n = 10), Slc39a14^+/− (n = 9), and Slc39a14^−/− (n = 15) mice. (D) In vitro ⁵⁹Fe-NTBI uptake by cultures of primary hepatocytes isolated from 13-wk-old WT and Slc39a14^−/− mice. Data are presented as pmol ⁵⁹Fe per mg of protein (n = 3 per group). (E) In vivo ⁵⁹Fe-TBI uptake by various tissues of 6-wk-old WT and Slc39a14^−/− mice (n = 4–5 per group). Tissue uptake of ⁵⁹Fe from TBI was calculated as a percentage of whole-body cpm. Data are presented as percent of total body cpm. Significance was calculated by using Student’s t-test. All data are shown as the mean ± SEM. ***p < 0.001, *p < 0.05.